Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
Faculty Richard S Finn, MD
Professor, Department of Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Additional faculty to be announced.
Anthony El-Khoueiry, MD
Associate Director for Clinical Research
Chief, Section of Developmental Therapeutics/Phase I Program
Verna R Richter Chair in Cancer Research
USC Norris Comprehensive Cancer Center
Los Angeles, California
Moderator
To be announced.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Eisai Inc.
MODULE 1: Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC)
Long-term outcomes associated with potentially curative resection or ablation among patients with early-stage HCC
Historical data with adjuvant therapeutic approaches, such as sorafenib, for patients with HCC
Design, eligibility criteria and primary and secondary endpoints of the Phase III IMbrave050 study assessing atezolizumab/bevacizumab as adjuvant therapy for patients with completely resected or ablated HCC who are at high risk for disease recurrence
Available and emerging efficacy and safety data from IMbrave050; recent communication advising against the off-label use of adjuvant atezolizumab/bevacizumab
Other ongoing Phase III studies, such as EMERALD-2, CheckMate 9DX and KEYNOTE-937, evaluating adjuvant immune checkpoint inhibitor (ICI) therapy for HCC; estimated completion dates
MODULE 2: Recent Developments in the Management of Intermediate-Stage HCC
Current indications for transarterial chemoembolization (TACE) for patients with unresectable HCC; historical outcomes documented with this strategy
Design, eligibility criteria and primary and secondary endpoints of the Phase III EMERALD-1 study of TACE combined with durvalumab with or without bevacizumab for patients with unresectable HCC eligible for embolization
Published efficacy and safety data from EMERALD-1; progression-free survival benefit observed with TACE in combination with durvalumab/bevacizumab
Potential clinical role of TACE in combination with durvalumab/bevacizumab for intermediate-stage HCC
Design, eligibility criteria and key efficacy and safety endpoints of the Phase III LEAP-012 trial evaluating TACE with or without lenvatinib and pembrolizumab for intermediate-stage HCC
Recently presented first interim analysis results of the LEAP-012 study and implications for the management of intermediate-stage HCC
Other ongoing Phase III trials investigating ICI-containing regimens in addition to or in lieu of TACE for patients with intermediate-stage HCC
MODULE 3: Current First-Line Therapy for Advanced HCC
Long-term findings from the Phase III IMbrave150 study comparing first-line atezolizumab/bevacizumab to sorafenib for advanced unresectable HCC
Correlation between antidrug antibody levels and clinical outcomes after treatment with atezolizumab/bevacizumab for advanced HCC
Published efficacy and safety findings, including 5-year overall survival (OS) results, from the Phase III HIMALAYA trial evaluating the combination of durvalumab/tremelimumab for patients with previously untreated advanced HCC
Effect of comorbidity profile, hepatic reserve and other factors on the selection between up-front atezolizumab/bevacizumab and durvalumab/tremelimumab for advanced HCC
Indications for tyrosine kinase inhibitor (TKI) monotherapy as first-line therapy for unresectable HCC; appropriate selection of patients for treatment with sorafenib or lenvatinib
MODULE 4: Promising Investigational Front-Line Strategies for Advanced HCC
Design, eligibility criteria and primary and secondary endpoints of the Phase III CheckMate 9DW study of nivolumab in combination with ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable HCC
OS and other key efficacy and safety outcomes achieved in CheckMate 9DW
Potential role of up-front nivolumab/ipilimumab for patients with advanced HCC
Mechanistic similarities and differences between toripalimab and other anti-PD-1/PD-L1 antibodies; early data with toripalimab combined with bevacizumab for previously untreated advanced HCC
Emerging positive findings from the Phase III HEPATORCH study of toripalimab/bevacizumab versus sorafenib for patients with unresectable or metastatic HCC; anticipated full readout and clinical implications
Published Phase III data with other novel front-line immunotherapeutic strategies for advanced HCC, such as camrelizumab/rivoceranib and tislelizumab
MODULE 5: Selection and Sequencing of Therapy for Relapsed/Refractory HCC
Effect of patient- and disease-related factors, validated biomarkers and prior exposure and response to treatment on clinical decision-making for advanced HCC that has progressed on first and consecutive lines of therapy
Role of approved first-line multitargeted TKIs, such as sorafenib and lenvatinib, among patients with relapsed disease
Long-term outcomes with approved anti-angiogenic agents, such as regorafenib, cabozantinib and ramucirumab, for patients with progressive HCC
Key findings with anti-PD-1/PD-L1 antibody-based strategies for progressive HCC; role, if any, for patients who have experienced disease progression on first-line immunotherapeutic approaches
Other novel agents and strategies under investigation for patients with advanced HCC
Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of hepatocellular carcinoma.
Learning Objectives
Upon completion of this activity, participants should be able to
Appreciate recently announced trial results with anti-PD-L1 antibody therapy in combination with anti-VEGF therapy as adjuvant treatment for patients with hepatocellular carcinoma (HCC) and a high risk of recurrence after curative resection or ablation, and avoid this approach in clinical practice.
Recall recently presented and emerging trial results with anti-PD-L1 antibody therapy in combination with anti-VEGF therapy for patients with HCC receiving transarterial chemoembolization for unresectable disease, and consider the potential role of this strategy in clinical practice.
Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first-line therapy for patients with unresectable or metastatic HCC.
Evaluate the scientific rationale for and available data with anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for patients with HCC, and optimally incorporate available regimens into the management of this disease.
Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
Review available and emerging data with investigational agents and strategies with documented efficacy in HCC in preparation for potential availability or to enhance clinical trial participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
Dr Finn — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, CStone Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, Lilly, Merck, Pfizer Inc; Contracted Research: Bristol Myers Squibb, Eisai Inc, Genentech, a member of the Roche Group, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Genentech, a member of the Roche Group.
Additional faculty disclosures to be announced.
MODERATOR To be announced.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Eisai Inc.
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600
Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2025 ASCO Gastrointestinal Cancers Symposium is taking place.
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of hepatocellular carcinoma.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ASCO Gastrointestinal Cancers Symposium.
IN-PERSON registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2025 ASCO® Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
